Cargando…
Biosimilar Naming Conventions: Pharmacist Perceptions and Impact on Confidence in Dispensing Biologics
BACKGROUND: The approval of the first biosimilar in the United States has placed increased pressure on the FDA to provide guidance on the naming convention that will be assigned to current and future biosimilars. The release of the FDA draft guidance on nonproprietary naming of biosimilars in August...
Autor principal: | Tomaszewski, Daniel |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Academy of Managed Care Pharmacy
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10398106/ https://www.ncbi.nlm.nih.gov/pubmed/27459654 http://dx.doi.org/10.18553/jmcp.2016.22.8.919 |
Ejemplares similares
-
Community pharmacists' preparedness for substituting biologics and dispensing biosimilars – Lessons learned from a multinational survey
por: Arnet, Isabelle, et al.
Publicado: (2021) -
Biosimilars: The naming puzzle
por: Gaur, Rajneesh Kumar
Publicado: (2015) -
Assessing consumers’ perception and demand on the community pharmacists’ dispensing
por: Xuan, Yapp Wen, et al.
Publicado: (2023) -
Consumers’ perceptions on the contribution of community pharmacists in the dispensing process at Dawadmi
por: Alotaibi, Hamoud Saud, et al.
Publicado: (2015) -
Pharmacists' confidence in explaining biosimilars to patients before a nationwide medicine change: A cross-sectional study
por: Gasteiger, Chiara, et al.
Publicado: (2022)